View More View Less
  • 1 Országos Reumatológiai és Fizioterápiás Intézet, Budapest, Frankel Leó út 38–40., 1023
Restricted access

Cross Mark

Absztrakt

A szerzők közleményükben a lupus nephritis kezelésének legújabb irányelvei mellett bemutatják saját mycofenolat mofetillel szerzett tapasztalataikat a betegség kezelésében. A lupus nephritis és főleg a proliferatív formája olyan gyakori és komoly manifesztációja a szisztémás lupus erythematosusnak, amely végstádiumú veseelégtelenséghez vagy akár halálhoz is vezethet. Az elmúlt évtizedekben a lupus nephritis kezelése sokat fejlődött, ma már a kedvezőbb mellékhatás-profilú mycofenolat mofetil a cyclophosphamid alternatívájává vált a III-as és IV-es osztályú glomerulonephritis indukciós és fenntartó kezelésében. Lupus nephritis diagnózissal eddig 25 betegüknek kértek egyedi méltányosság alapján támogatást mycofenolat mofetil adására. Szövettanilag legtöbben a WHO III (A/C) és IV (A) szövettani osztályába tartoztak (30-30%), beszűkült vesefunkció csak 16%-ukban volt jelen. Glükokortikoid és cyclophosphamid indukciós kezelés után adott mycofenolatterápia mellett az átlagos napi proteinuria 3,18 g/napról 1,06 g/napra csökkent. A betegek 24%-ánál jött létre komplett, 48%-ánál részleges remisszió. Ezek alapján a mycofenolat mofetil hatékony kezelésnek tartható a proliferatív lupus nephritis kezelésében. Orv. Hetil., 2016, 157(35), 1385–1393.

  • 1

    Maroz, N., Segal, M. S.: Lupus nephritis and end-stage kidney disease. Am. J. Med. Sci., 2013, 346(4), 319–323.

  • 2

    Hsu, C. Y., Chiu, W. C., Yang, T. S., et al.: Age- and gender-related long-term renal outcome in patients with lupus nephritis. Lupus, 2011, 20(11), 1135–1141.

  • 3

    Ippolito, A., Petri, M.: An update on mortality in systemic lupus erythematosus. Clin. Exp. Rheumatol., 2008, 26(5 Suppl. 51), S72–S79.

  • 4

    Imran, T. F., Yick, F., Verma, S., et al.: Lupus nephritis: an update. Clin. Exp. Nephrol., 2016, 20(1), 1–13.

  • 5

    Austin, H. A. 3rd, Muenz, L. R., Joyce, K. M., et al.: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am. J. Med., 1983, 75(3), 382–391.

  • 6

    Cooper, G. S., Dooley, M. A., Treadwell, E. L., et al.: Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J. Clin. Epidemiol., 2002, 55(10), 982–989.

  • 7

    Boackle, S. A.: Advances in lupus genetics. Curr. Opin. Rheumatol., 2013, 25(5), 561–568.

  • 8

    Kiss, E.: Lupus nephritis. In: Kakuk, G. (ed.): Clinical nephrology. [Lupus nephritis. In: Kakuk, G. (szerk.): Klinikai nephrologia.] Medicina Könyvkiadó, Budapest, 2004. [Hungarian]

  • 9

    Blanco, P., Ueno, H., Schmitt, N.: T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis. Eur. J. Immunol., 2016, 46(2), 281–290.

  • 10

    Weening, J. J., D’Agati, V. D., Schwartz, M. M., et al.: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol., 2004, 15(2), 241–250.

  • 11

    Balow, J. E.: Clinical presentation and monitoring of lupus nephritis. Lupus, 2005, 14(1), 25–30.

  • 12

    Gonzalez-Crespo, M. R., Lopez-Fernandez, J. I., Usera, G., et al.: Outcome of silent nephritis. Semin. Arthritis Rheum., 1996, 26(1), 468–476.

  • 13

    Wakasugi, D., Gono, T., Kawaguchi, Y., et al.: Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J. Rheumatol., 2012, 39(1), 79–85.

  • 14

    Moroni, G., Quaglini, S., Gravellone, L., et al.: Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients. Semin. Arthritis Rheum., 2012, 41(5), 642–651.

  • 15

    Pasquali, S., Banfi, G., Zucchelli, A., et al.: Lupus membranous nephropathy: long term outcome. Clin. Nephrol., 1993, 39(4), 175–182.

  • 16

    Chan, T. M.: Preventing renal failure in patients with severe lupus nephritis. Kidney Int. Suppl., 2005, 67, S116–S119.

  • 17

    Houssiau, F. A., Vasconcelos, C., D’Cruz, D., et al.: Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum., 2004, 50(12), 3934–3940.

  • 18

    Hahn, B. H., McMahon, M. A., Wilkinson, A., et al.: American College of Rheumatology guidelines for screening, treatment and management of lupus nephritis. Arthritis Care Res., 2012, 64(6), 797–808.

  • 19

    KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int. Suppl., 2012, 2(2), 139–274.

  • 20

    Jafar, T. H., Stark, P. C., Schmid, C. H., et al.: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med., 2003, 139(4), 244–252.

  • 21

    Durán-Barragán, S., McGwin, G. Jr., Vilá, L. M., et al.: Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus – results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford), 2008, 47(7), 1093–1096.

  • 22

    The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum., 2006, 54(2), 421–432.

  • 23

    Contreras, G., Pardo, V., Leclercq, B., et al.: Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med., 2004, 350(10), 971–980.

  • 24

    Houssiau, F. A., Vasconcelos, C., D’Cruz, D., et al.: Immunosupressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum., 2002, 46(8), 2121–2131.

  • 25

    Houssiau, F. A., Vasconcelos, C., D’Cruz, D., et al.: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis., 2010, 69(1), 61–64.

  • 26

    Chan, T. M., Tse, K. C., Tang, C. S., et al.: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol., 2005, 16(4), 1076–1084.

  • 27

    Touma, Z., Gladman, D. D., Urowitz, M. B., et al.: Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J. Rheumatol., 2011, 38(1), 69–78.

  • 28

    Ginzler, E. M., Appel, G. B., Dooley, M. A., et al.: Aspreva Lupus Management Study (ALMS) maintenance results. [Abstract.] Arthritis Rheum., 2010, 62(Suppl. 10), 2085.

  • 29

    Budde, K., Glander, P., Diekmann, F., et al.: Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin. Pharmacother., 2004, 5(6), 1333–1345.

  • 30

    Budde, K., Dürr, M., Liefeldt, L., et al.: Enteric-coated mycophenolate sodium. Expert Opin. Drug Saf., 2010, 9(6), 981–994.

  • 31

    Boumpas, D. T., Austin, H. A. 3rd, Vaughn, E. M., et al.: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet, 1992, 340(8822), 741–745.

  • 32

    Deng, J., Huo, D., Wu, Q., et al.: A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J. Exp. Med., 2012, 227(4), 281–288.

  • 33

    Rovin, B. H., Furie, R., Latinis, K., et al.: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum., 2012, 64(4), 1215–1226.

  • 34

    Boumpas, D. T., Austin, H. A. 3rd, Vaughan, E. M., et al.: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Intern. Med., 1993, 119(5), 366–369.

  • 35

    Houssiau, F. A., D’Cruz, D., Sangle, S., et al.: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis., 2010, 69(12), 2083–2089.

  • 36

    Bertsias, G. K., Tektonidou, M., Amoura, Z., et al.: Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis., 2012, 71(11), 1771–1782.

  • 37

    Moroni, G., Gallelli, B., Quaglini, S., et al.: With drawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol. Dial. Transplant., 2006, 21(6), 1541–1548.

  • 38

    Austin, H. A. 3rd, Illei, G. G., Braun, M. J., et al.: Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol., 2009, 20(4), 901–911.

  • 39

    Radhakrishnan, J., Moutzouris, D. A., Ginzler, E. M., et al.: Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int., 2010, 77(2), 152–160.

  • 40

    Van Vollenhoven, R. F., Parodis, I., Levitsky, A.: Biologics in SLE: towards new aproaches. Best Pract. Res. Clin. Rheumatol., 2013, 27(3), 341–349.

  • 41

    Gatto, M., Kiss, E., Naparstek, Y., et al.: In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med., 2014, 12, 30.

  • 42

    Borchers, A. T., Leibushor, N., Naguwa, S. M., et al.: Lupus nephritis: a critical review. Autoimmun. Rev., 2012, 12(2), 174–194.

  • 43

    Houssiau, F. A., Lauwerys, B. R.: Current management of lupus nephritis. Best Pract. Res. Clin. Rheumatol., 2013, 27(3), 319–328.

  • 44

    Fangtham, M., Petri, M.: 2013 update: Hopkins lupus cohort. Curr. Rheumatol. Rep., 2013, 15(9), 360.

  • 45

    Fessler, B. J., Alarcón, G. S., McGwin, G. Jr., et al.: Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum., 2005, 52(5), 1473–1480.

  • 46

    Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., et al.: Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis., 2010, 69(1), 20–28.

  • 47

    Szántó, S., Kiss, E., Szegedi, Gy.: Lupus nephritis and kidney transplantation. [A lupus nephritis és a vesetranszplantáció.] Allergol. Klin. Immunol., 1999, 2(1), 11–15. [Hungarian]

  • 48

    Ward, M. M.: Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. Kidney Int., 2000, 57(5), 2136–2143.

  • 49

    Moroni, G., Tantardini, F., Gallelli, B., et al.: The long-term prognosis of renal transplantation in patients with lupus nephritis. Am. J. Kidney Dis., 2005, 45(5), 903–911.

  • 50

    http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=19685

All Time Past Year Past 30 Days
Abstract Views 103 103 9
Full Text Views 26 9 0
PDF Downloads 31 12 0